Literature DB >> 11895618

A genetic disorder of lymphocyte apoptosis involving the fas pathway: the autoimmune lymphoproliferative syndrome.

T A Fleisher1, S E Straus, J J Bleesing.   

Abstract

Autoimmune lymphoproliferative syndrome (ALPS) is a recently characterized human disorder that typically presents with lymphocyte accumulation in the first few years of life. This is often associated with the development of autoimmunity, most commonly affecting the hematopoietic system. A key laboratory feature is the marked expansion of double-negative (CD4- and CD8-) T cells that express the alpha/beta T-cell receptor. ALPS is associated with defective Fas-mediated lymphocyte apoptosis, and in most patients, this results from a heterozygous mutation in the TNFRSF6 gene encoding Fas. The clinical features of ALPS reveal the importance of the Fas apoptotic pathway in maintaining lymphocyte homeostasis and protecting against autoimmunity and lymphoid malignancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11895618     DOI: 10.1007/s11882-001-0062-y

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  33 in total

1.  Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations.

Authors:  R M Siegel; J K Frederiksen; D A Zacharias; F K Chan; M Johnson; D Lynch; R Y Tsien; M J Lenardo
Journal:  Science       Date:  2000-06-30       Impact factor: 47.728

2.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

Review 3.  The molecular biology of apoptosis.

Authors:  D L Vaux; A Strasser
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

4.  Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease.

Authors:  A M Peters; B Kohfink; H Martin; F Griesinger; B Wörmann; M Gahr; J Roesler
Journal:  Exp Hematol       Date:  1999-05       Impact factor: 3.084

Review 5.  The role of Fas and related death receptors in autoimmune and other disease states.

Authors:  R M Siegel; T A Fleisher
Journal:  J Allergy Clin Immunol       Date:  1999-05       Impact factor: 10.793

6.  Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humoral autoimmunity.

Authors:  I J Fuss; W Strober; J K Dale; S Fritz; G R Pearlstein; J M Puck; M J Lenardo; S E Straus
Journal:  J Immunol       Date:  1997-02-15       Impact factor: 5.422

Review 7.  Genetics of systemic autoimmunity in mouse models of lupus.

Authors:  D H Kono; A N Theofilopoulos
Journal:  Int Rev Immunol       Date:  2000       Impact factor: 5.311

8.  Clinical, immunological, and pathological consequences of Fas-deficient conditions.

Authors:  F Le Deist; J F Emile; F Rieux-Laucat; M Benkerrou; I Roberts; N Brousse; A Fischer
Journal:  Lancet       Date:  1996-09-14       Impact factor: 79.321

9.  Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation.

Authors:  B J Sleight; V S Prasad; C DeLaat; P Steele; E Ballard; R J Arceci; C L Sidman
Journal:  Bone Marrow Transplant       Date:  1998-08       Impact factor: 5.483

10.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.

Authors:  R Watanabe-Fukunaga; C I Brannan; N G Copeland; N A Jenkins; S Nagata
Journal:  Nature       Date:  1992-03-26       Impact factor: 49.962

View more
  2 in total

1.  Loss-of-function of the protein kinase C δ (PKCδ) causes a B-cell lymphoproliferative syndrome in humans.

Authors:  Hye Sun Kuehn; Julie E Niemela; Andreia Rangel-Santos; Mingchang Zhang; Stefania Pittaluga; Jennifer L Stoddard; Ashleigh A Hussey; Moses O Evbuomwan; Debra A Long Priel; Douglas B Kuhns; C Lucy Park; Thomas A Fleisher; Gulbu Uzel; João B Oliveira
Journal:  Blood       Date:  2013-02-21       Impact factor: 22.113

2.  Stimulation of Fas agonistic antibody-mediated apoptosis by heparin-like agents suppresses Hsp27 but not Bcl-2 protective activity.

Authors:  Florence Manero; Vesna Ljubic-Thibal; Maryline Moulin; Nadège Goutagny; Jean-Claude Yvin; André-Patrick Arrigo
Journal:  Cell Stress Chaperones       Date:  2004       Impact factor: 3.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.